Fair enough Trout and PTX too several years ago.
Success in biotech oncology is not easy.
Especially on the world stage as a small Aussie battler.
There will be failures along the way. Ask Thomas Edison.
Investors who want low risk capital returns and dividends are in the wrong end of town.
Question posed was:-
Does IMM need a entrepreneur type chairman or scientific academic to set the ships course to its ultimate destination(s).
For me at this stage of our development, I want a dynamic deal maker, as the science is all but proven in key P2 trials.
Driving Competitive tension between BP's or/and others should be part of the chairs remit.
Fair enough Trout and PTX too several years ago. Success in...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |